论文部分内容阅读
目的:探讨硝苯地平控释片联合替米沙坦治疗糖尿病合并高血压临床效果及对血同型半胱氨酸（Hcy）、C-反应蛋白（CRP）的影响。方法:选取2016年2月至2019年11月安徽省淮南市第一人民医院收治的84例糖尿病合并高血压患者，采用随机数字表法分为联合组和对照组各42例。对照组给予硝苯地平控释片治疗，联合组在此基础上加予替米沙坦，两组均连续治疗4周。治疗结束后评估两组临床疗效，检测治疗前后舒张压（DBP）、收缩压（SBP）、空腹血糖（FPG）、餐后2 h血糖（2 hPG）、糖化血红蛋白（HbAn 1c）、总胆固醇（TC）、三酰甘油（TG）、Hcy、CRP水平，记录不良反应发生例数。n 结果:治疗后联合组总有效率为92.24%（40/42），明显高于对照组的80.95%（34/42），差异有统计学意义（n P 0.05），但联合组治疗后的SBP、DBP、TC、TG、CRP、Hcy水平明显低于对照组治疗后[（132.64 ± 7.53） mmHg）（1 mmHg ＝ 0.133 kPa）比（142.81 ± 4.63） mmHg）、（79.63 ± 6.84） mmHg比（85.71 ± 5.86） mmHg、（4.87 ± 0.61） mmol/L比（5.14 ± 0.62） mmol/L、（1.57 ± 0.41）mmol/L比（1.76 ± 0.45） mmol/L、（8.76 ± 1.53） mg/L比（9.51 ± 1.86） mg/L、（12.52 ± 1.97） μmol/L比（13.48 ± 2.36） μmol/L]，差异有统计学意义（ n P 0.05）。n 结论:硝苯地平控释片联合替米沙坦治疗糖尿病合并高血压临床疗效较优，能调节血压、血脂、Hcy、CRP水平，缓解病情进展，且安全性良好。“,”Objective:To explore the clinical curative effect of nifedipine controlled-release tablets combined with telmisartan on diabetes mellitus combined with hypertension and their influences on serum homocysteine (Hcy) and C-reactive protein (CRP).Methods:Eighty-four patients with diabetes mellitus and hypertension who were admitted to Huainan First People′s Hospital from February 2016 to November 2019 were enrolled. They were divided into combination group and control group by random number table method, with 42 cases in each group. The control group was treated with nifedipine controlled-release tablets, while combination group was additionally treated with telmisartan. Both groups were continuously treated for 4 weeks. After treatment, clinical curative effect in both groups was evaluated. The levels of diastolic blood pressure (DBP), systolic blood pressure (SBP), fasting plasma glucose (FPG), 2 h postprandial blood glucose (2 hPG), glycosylated hemoglobin (HbAn 1c), total cholesterol (TC), triacylglycerol (TG), Hcy and CRP were measured before and after treatment. The number of cases with adverse reactions was recorded.n Results:After treatment, total response rate in combination group was significantly higher than that in control group [92.24%(40/42) vs. 80.95%(34/42)] (n P0.05). After treatment, the levels of SBP, DBP, TC, TG, CRP and Hcy in combination group were significantly lower than those in control group [(132.64 ± 7.53) mmHg)(1 mmHg=0.133 kPa) vs. (142.81 ± 4.63) mmHg, (79.63 ± 6.84) mmHg vs.(85.71 ± 5.86) mmHg, (4.87 ± 0.61) mmol/L vs. (5.14 ± 0.62) mmol/L, (1.57 ± 0.41) mmol/L vs.(1.76 ± 0.45) mmol/L,(8.76 ± 1.53) mg/L vs. (9.51 ± 1.86) mg/L, (12.52 ± 1.97) μmol/L vs.(13.48 ± 2.36) μmol/L](n P0.05).n Conclusions:The clinical curative effect of nifedipine controlled-release tablets combined with telmisartan is good on diabetes mellitus combined with hypertension, which can regulate blood pressure, blood lipids, Hcy and CRP levels, and relieve disease progression, with good safety.